COVID-19 vaccination in patients with immunity-mediated kidney disease

Vaccination against SARS-CoV-2 seems to be safe in patients with immunity-mediated kidney disease, although their immunological responses to vaccination are impaired. Further strategies, including the administration of additional vaccine doses and passive immunization with long-acting monoclonal ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Prendecki, Maria, Willicombe, Michelle, McAdoo, Stephen P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525453/
https://www.ncbi.nlm.nih.gov/pubmed/34667284
http://dx.doi.org/10.1038/s41581-021-00502-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525453/
https://www.ncbi.nlm.nih.gov/pubmed/34667284
http://dx.doi.org/10.1038/s41581-021-00502-7

Ejemplares similares